94 related articles for article (PubMed ID: 23506972)
1. A single-center prospective randomized controlled trial evaluating the safety and efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion: gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'.
Suh JW; Yoon YE; Oh IY; Yoon CH; Cho YS; Youn TJ; Chae IH; Choi DJ
Contemp Clin Trials; 2013 May; 35(1):145-50. PubMed ID: 23506972
[TBL] [Abstract][Full Text] [Related]
2. Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial.
Roubille F; Micheau A; Combes S; Thibaut S; Souteyrand G; Cayla G; Bonello L; Lesavre N; Sportouch-Dukhan C; Klein F; Berboucha S; Cade S; Cung TT; Raczka F; Macia JC; Gervasoni R; Cransac F; Leclercq F; Barrère-Lemaire S; Paganelli F; Mottref P; Vernhet Kovacsik H; Ovize M; Piot C
Arch Cardiovasc Dis; 2013 Mar; 106(3):135-45. PubMed ID: 23582675
[TBL] [Abstract][Full Text] [Related]
3. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.
Prunier F; Bière L; Gilard M; Boschat J; Mouquet F; Bauchart JJ; Charbonnier B; Genée O; Guérin P; Warin-Fresse K; Durand E; Lafont A; Christiaens L; Abi-Khalil W; Delépine S; Benard T; Furber A
Am Heart J; 2012 Feb; 163(2):200-7.e1. PubMed ID: 22305837
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion-Gauging Infarct Size in Patients with Acute ST-segment Elevation Myocardial Infarction (ICEBERG).
Seo WW; Suh JW; Oh IY; Yoon CH; Cho YS; Youn TJ; Chae IH; Choi DJ
Int Heart J; 2019 Mar; 60(2):255-263. PubMed ID: 30799375
[TBL] [Abstract][Full Text] [Related]
5. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
6. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.
Najjar SS; Rao SV; Melloni C; Raman SV; Povsic TJ; Melton L; Barsness GW; Prather K; Heitner JF; Kilaru R; Gruberg L; Hasselblad V; Greenbaum AB; Patel M; Kim RJ; Talan M; Ferrucci L; Longo DL; Lakatta EG; Harrington RA;
JAMA; 2011 May; 305(18):1863-72. PubMed ID: 21558517
[TBL] [Abstract][Full Text] [Related]
7. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study.
Lipsic E; van der Meer P; Voors AA; Westenbrink BD; van den Heuvel AF; de Boer HC; van Zonneveld AJ; Schoemaker RG; van Gilst WH; Zijlstra F; van Veldhuisen DJ
Cardiovasc Drugs Ther; 2006 Apr; 20(2):135-41. PubMed ID: 16761193
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction.
Chakrabarti AK; Feeney K; Abueg C; Brown DA; Czyz E; Tendera M; Janosi A; Giugliano RP; Kloner RA; Weaver WD; Bode C; Godlewski J; Merkely B; Gibson CM
Am Heart J; 2013 Apr; 165(4):509-514.e7. PubMed ID: 23537966
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'.
Kang HJ; Kim MK; Kim MG; Choi DJ; Yoon JH; Park YB; Kim HS
Trials; 2011 Feb; 12():33. PubMed ID: 21299845
[TBL] [Abstract][Full Text] [Related]
10. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Grygier M; Araszkiewicz A; Lesiak M; Janus M; Kowal J; Skorupski W; Pyda M; Mitkowski P; Grajek S
Am J Cardiol; 2011 Apr; 107(8):1131-5. PubMed ID: 21310372
[TBL] [Abstract][Full Text] [Related]
11. Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.
Nyolczas N; Gyöngyösi M; Beran G; Dettke M; Graf S; Sochor H; Christ G; Edes I; Balogh L; Krause KT; Jaquet K; Kuck KH; Benedek I; Hintea T; Kiss R; Préda I; Kotevski V; Pejkov H; Dudek D; Heba G; Sylven C; Charwat S; Jacob R; Maurer G; Lang I; Glogar D
Am Heart J; 2007 Feb; 153(2):212.e1-7. PubMed ID: 17239678
[TBL] [Abstract][Full Text] [Related]
12. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction.
Stone GW; Martin JL; de Boer MJ; Margheri M; Bramucci E; Blankenship JC; Metzger DC; Gibbons RJ; Lindsay BS; Weiner BH; Lansky AJ; Krucoff MW; Fahy M; Boscardin WJ;
Circ Cardiovasc Interv; 2009 Oct; 2(5):366-75. PubMed ID: 20031745
[TBL] [Abstract][Full Text] [Related]
13. Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): a randomized controlled clinical trial.
Minamino T; Toba K; Higo S; Nakatani D; Hikoso S; Umegaki M; Yamamoto K; Sawa Y; Aizawa Y; Komuro I;
Cardiovasc Drugs Ther; 2012 Oct; 26(5):409-16. PubMed ID: 22940818
[TBL] [Abstract][Full Text] [Related]
14. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.
Melloni C; Rao SV; Povsic TJ; Melton L; Kim RJ; Kilaru R; Patel MR; Talan M; Ferrucci L; Longo DL; Lakatta EG; Najjar SS; Harrington RA
Am Heart J; 2010 Nov; 160(5):795-803.e2. PubMed ID: 21095264
[TBL] [Abstract][Full Text] [Related]
15. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial.
Ludman AJ; Yellon DM; Hasleton J; Ariti C; Babu GG; Boston-Griffiths E; Venugopal V; Walker M; Holdright D; Swanton H; Crake T; Brull D; Moon JC; Puranik R; Muthurangu V; Taylor A; Hausenloy DJ
Heart; 2011 Oct; 97(19):1560-5. PubMed ID: 21900585
[TBL] [Abstract][Full Text] [Related]
16. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
; Bates E; Bode C; Costa M; Gibson CM; Granger C; Green C; Grimes K; Harrington R; Huber K; Kleiman N; Mochly-Rosen D; Roe M; Sadowski Z; Solomon S; Widimsky P
Circulation; 2008 Feb; 117(7):886-96. PubMed ID: 18250271
[TBL] [Abstract][Full Text] [Related]
17. Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention.
O'Neill WW; Martin JL; Dixon SR; Bartorelli AL; Trabattoni D; Oemrawsingh PV; Atsma DE; Chang M; Marquardt W; Oh JK; Krucoff MW; Gibbons RJ; Spears JR;
J Am Coll Cardiol; 2007 Jul; 50(5):397-405. PubMed ID: 17662390
[TBL] [Abstract][Full Text] [Related]
18. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.
Amit G; Cafri C; Yaroslavtsev S; Fuchs S; Paltiel O; Abu-Ful A; Weinstein JM; Wolak A; Ilia R; Zahger D
Am Heart J; 2006 Nov; 152(5):887.e9-14. PubMed ID: 17070151
[TBL] [Abstract][Full Text] [Related]
19. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction.
Desmet W; Bogaert J; Dubois C; Sinnaeve P; Adriaenssens T; Pappas C; Ganame J; Dymarkowski S; Janssens S; Belmans A; Van de Werf F
Eur Heart J; 2011 Apr; 32(7):867-77. PubMed ID: 21196444
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Atar D; Huber K; Rupprecht HJ; Kopecky SL; Schwitter J; Theek C; Brandl K; Henning R; Geudelin B
Cardiology; 2007; 108(2):117-23. PubMed ID: 17019083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
